CRSP
Crispr Therapeutics AG
NASDAQ: CRSP · HEALTHCARE · BIOTECHNOLOGY
$50.71
-2.59% today
Updated 2026-04-29
Market cap
$4.70B
P/E ratio
—
P/S ratio
1,340.31x
EPS (TTM)
$-6.47
Dividend yield
—
52W range
$33 – $78
Volume
2.0M
Crispr Therapeutics AG (CRSP) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-4.79M | $59.43M | $-55.31M | $-70.10M | $-96.24M | $56.68M | $-238.37M | $538.97M | $-495.74M | $-260.38M | $-142.77M | $-345.01M |
| Capital expenditures | $1.15M | $1.15M | $3.02M | $7.81M | $2.77M | $6.68M | $18.36M | $81.70M | $37.19M | $9.47M | $1.90M | $914000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $695000.00 | $3.68M | $10.84M | $18.87M | $34.98M | $44.06M | $66.02M | $102.39M | $97.95M | $81.03M | $86.57M | $72.50M |
| Free cash flow | $-5.95M | $58.27M | $-58.33M | $-77.91M | $-99.01M | $49.99M | $-256.72M | $457.27M | $-532.93M | $-269.85M | $-144.68M | $-345.93M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $159.56M | $-75.76M | $216.92M | $488.99M | $236.62M | $-245.51M | $-715.80M | — | — | — |